Aug 2026· Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi· Vol 47 8, pp.
771-776
· 0 citations
Medicine
TL;DR
The case preliminarily supports the feasibility and potential clinical value of in vivo CAR-T cell therapy in high-risk, heavily pretreated B-ALL patients and provides a valuable practical reference for clinical application.
Donor-derived anti-CD19 chimeric antigen receptor T-cell (CAR T-cell) therapy has emerged as one of the most promising treatments for relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). In this retrospective study, we evaluated the safety and efficacy of donor-derived anti-CD19 CAR T cells manufactur...
Supavich Tannumsaeng, U. Anurathapan, Arpatsorn Sermcheep et al.· Cancer Chemotherapy and Phar...· 0 citations
The unmet needs in patients with high-risk disease and the challenges of sequencing these therapeutic strategies are discussed, while providing expert clinical practice recommendations to optimize patient outcomes are provided.
P. Caimi, Romano Danesi, G. Iacoboni et al.· Blood reviews· 0 citations
In this nonrandomized clinical trial, bicistronic CD19/CD22 CAR T-cell therapy induced high rates of minimal residual disease-negative remission, with durable EFS in pediatric B-ALL, and support further evaluation in prospective trials.
Xinyu Wan, Yan-Jing Tang, Jiao-Yang Cai et al.· JAMA Oncology· 1 citation
BACKGROUND
Relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL) remains challenging to treat, particularly in patients ineligible for high-dose chemotherapy and autologous stem cell transplantation. Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising treatment.
AIMS
We describe the e...
Julie Vandewiele, Chiel Gharakhani, C. De Vriendt et al.· Acta Clinica Belgica· 0 citations
Background T-cell acute lymphoblastic leukemia (T-ALL) with ABL1 rearrangement is an extremely rare disease, and its clinical significance has not been precisely defined. We report the clinical characteristics of a pediatric patient with T-cell acute lymphoblastic leukemia harboring ABL1 rearrangement and the treatment...
Ming-Yan Zhong, Wen-Ting He, Ling-Ji Zeng et al.· Frontiers in Oncology· 0 citations
